Fludarabine Injection (Fludarabine Phosphate Injection) - Drug Interactions, Contraindications, Overdosage, etc

DRUG INTERACTIONS

Drug Interactions

The use of Fludarabine Phosphate for Injection, USP in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity (see WARNINGS section).

OVERDOSAGE

High doses of Fludarabine Phosphate for Injection, USP (see WARNINGS section) have been associated with an irreversible central nervous system toxicity characterized by delayed blindness, coma and death. High doses are also associated with severe thrombocytopenia and neutropenia due to bone marrow suppression. There is no known specific antidote for Fludarabine Phosphate for Injection, USP overdosage. Treatment consists of drug discontinuation and supportive therapy.

CONTRAINDICATIONS

Fludarabine Phosphate for Injection, USP is contraindicated in those patients who are hypersensitive to this drug or its components.

REFERENCES

1. Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. NIOSH Alert 2004-165.

2. OSHA Technical Manual, TED 1-0. 15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm vi 2.html

3. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006: 63 1172-1193.

4. Polvich, M., White, J.M., & Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2^nd ed.). Pittsburgh, PA: Oncology Nursing Society

Mfd. for SAGENT Pharmaceuticals
Schaumburg, IL 60195 (USA)
Made in Romania
©2009 Sagent Pharmaceuticals, Inc.

June 2009